Loading...
•
Jun 30, 2024
Tscan Therapeutics Q2 2024 Earnings Report
TScan Therapeutics reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.
Key Takeaways
TScan Therapeutics reported second quarter 2024 financial results, including revenue of $0.5 million and a net loss of $31.7 million. The company received RMAT designation for TSC-100 and TSC-101 and engaged a CDMO for manufacturing. They expect to report initial data from the solid tumor program and one-year data from the ALLOHATM Phase 1 heme trial by the end of 2024 and cash is expected to fund operations into Q4 2026.
FDA granted RMAT designation to TSC-100 and TSC-101 for AML, ALL, and MDS treatment.
Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization.
On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024.
Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026.
Tscan Therapeutics
Tscan Therapeutics
Tscan Therapeutics Revenue by Segment
Revenue by Segment
Collab & License Revenue
CapyFin.com Forward Guidance
TScan anticipates several milestones in their Heme Malignancies and Solid Tumor programs.
Positive Outlook
- Opening of expansion cohorts at the proposed recommended Phase 2 dose level to further characterize safety and evaluate translational and efficacy endpoints is planned for the third quarter of 2024.
- Reporting of one-year clinical and translational data on initial patients is anticipated by the end of 2024.
- Initiation of a registration trial, pending feedback from regulatory authorities, and reporting of two-year clinical and translational data are anticipated in 2025.
- Initial singleplex data expected by the end of 2024.
- Response data for multiplex therapy anticipated in 2025.